Ovarian Cancer Research Alliance

Research. Advocacy. Support.

aka OCRA | New York, NY | www.ocrahope.org

GuideStar Charity Check

EIN: 13-3806788

Contributions tax deductible
as of September 2023

IRS BMF 509(a)(1)
as of September 18, 2023

View summary

Charity Check report

Mission

Ovarian Cancer Research Alliance (OCRA) is the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. As the voice for ovarian cancer, OCRA funds private research, advocates for increased federal research and awareness dollars and furthers policies that give women access to the services they need, as well as supports women and their families before, during and after a diagnosis. Collectively, the organization has invested over $110 million in private ovarian cancer research and has advocated to secure over $2.2 billion federal dollars dedicated to ovarian cancer research and awareness.

Ruling year info

1995

President & CEO

Ms. Audra Moran

Main address

14 Pennsylvania Plaza Suite 2110

New York, NY 10122 USA

Show more contact info

Formerly known as

Ann Schreiber Ovarian Cancer Research Fund

Ovarian Cancer Research Fund (OCRF)

Ovarian Cancer National Alliance

EIN

13-3806788

Subject area info

Philanthropy

Cancers

Population served info

Women and girls

Families

People with diseases and illnesses

Academics

NTEE code info

Cancer Research (H30)

Cancer (G30)

Alliance/Advocacy Organizations (T01)

IRS subsection

501(c)(3) Public Charity

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Tax forms

Show Forms 990

Communication

Affiliations

See related organizations info

Programs and results

Reports and documents

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Woman to Woman

OCRA’s Woman to Woman is a unique support program that pairs gynecologic cancer patients with trained survivor volunteers who provide one-on-one emotional support and mentoring to women when they need it most. From diagnosis through treatment and beyond, Woman to Woman survivor volunteers have helped hundreds of women and their families cope with gynecologic cancer.

Population(s) Served

Women and girls

People with diseases and illnesses

Ovarian Cancer National Conference

The Ovarian Cancer National Conference is the longest running conference devoted to ovarian cancer survivors. It is the epicenter for researchers, clinicians, survivors and friends to come together and learn from one another about developments in diagnosis, treatment and quality of life for women with ovarian cancer.

Population(s) Served

People with diseases and illnesses

Families

Survivors Teaching Students (STS)

This program utilizes trained ovarian cancer survivors to conduct presentations in educational programs to educate future healthcare providers about ovarian cancer by sharing stories of diagnosis and treatment, along with facts about the disease. Medical/healthcare students interact with and learn from actual patients in a classroom setting. STS has reached over 75,000 medical and healthcare students since inception.

Population(s) Served

People with diseases and illnesses

Academics

Research Grants

We fund scientists at every stage of their careers. The Ann and Sol Schreiber Mentored Investigator Award is for recent grads, just starting out in the field; the Liz Tilberis Early Career Award is for independent researchers building their own laboratories; and the Collaborative Research Development Grant is for teams of senior researchers working together on large projects. Over $85 million has been awarded to researchers working to cure ovarian cancer.

Population(s) Served

People with diseases and illnesses

Academics

Advocate Leaders

Since 2013, OCRA has trained people around the country through our Advocate Leaders program to raise awareness by developing relationships with their elected officials and advocating for increased funding for ovarian cancer research and related health policies at a grassroots level, as well as bringing them all together annually for Advocacy Day in Washington, D.C.

Population(s) Served

Women and girls

People with diseases and illnesses

Research Advocacy

OCRA trains ovarian cancer survivors interested in shaping the future of ovarian cancer research by serving as research advocates. Research advocates help funding agencies and scientists understand and prioritize the questions that are important to the ovarian cancer community. Having the input of survivors ensures that research is patient-focused and truly meets the needs of our community. Research advocates also report back to the community, sharing what they have learned, so that everyone can benefit from scientific progress.

Population(s) Served

Women and girls

People with diseases and illnesses

Where we work

External reviews

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

What is the organization aiming to accomplish?

Ultimately, Ovarian Cancer Research Fund Alliance's goal is to eradicate ovarian cancer-- the deadliest of all gynecologic cancers. Our mission is to promote, advocate for and support scientific research as it relates to the causes, prevention, diagnosis, treatment, and cure for ovarian cancer; to provide education about ovarian cancer; to promote, advocate for and provide supportive services to persons affected by ovarian cancer; and to foster alliances to further those purposes.

What are the organization's key strategies for making this happen?

Ovarian Cancer Research Fund Alliance unites the ovarian cancer community as one strong voice, propelling the ovarian cancer field forward at an accelerated pace—exactly what is needed at a critical time when scientific discoveries are rapidly increasing. We funding research through our own grant programs, we simultaneously work in Washington DC to increase federal dollars for research, and offer comprehensive education and patient engagement programs for women at all stages of diagnosis and survivorship.

What are the organization's capabilities for doing this?

OCRFA is the oldest and largest charity funding ovarian cancer research in the United States, and awards grants through a competitive peer-review process conducted by OCRFA's prestigious Scientific Advisory Committee. The Scientific Advisory Committee is comprised of the nation's top gynecologic oncologists and ovarian cancer researchers. OCRFA is nimble in its ability to fund the most novel approaches to combating this disease. OCRFA is able to solicit, review, and fund worthy applications in a relatively short time-frame, which leads to more rapid scientific progress.

OCRFA is deeply engaged in advocacy, and has successfully advocated for over $2.2 billion in federal funding for ovarian cancer research and education for the past two decades.

What have they accomplished so far and what's next?

OCRFA has been the driving force behind many important discoveries. In the past several years, OCRFA grantees have:

*Developed innovative strategies for early detection: OCRFA-funded research has shown that glycans (small sugar molecules in the blood) appear to distinguish between healthy women and those with ovarian cancer. OCRFA researchers are developing a pilot test.

*Discovered changes that increase risk for ovarian cancer: OCRFA funding has led to the identification of a new genetic polymorphism—like BRCA1/2 but more common—that may significantly increase a woman's risk of ovarian cancer.

*Illuminated the origins of ovarian cancer: OCRFA researchers developed a laboratory model that mimics the process by which fallopian tube cells may morph into cancer cells that appear to have come from the ovaries. This demonstration of what happens in patients furthers the theory that some ovarian cancers begin in the fallopian tube.

*Identified new and better targets for treatment: OCRFA researchers discovered that elevated blood platelet levels in ovarian cancer patients fuel tumor growth and reduce survival. These findings reveal a new factor in cancer progression, and also suggest that drugs that interfere with coagulation might be a useful addition to conventional therapies.

In our mission to educate future medical professionals about ovarian cancer, we are also making progress. In the last year alone our Survivors Teaching Students program, in which ovarian cancer survivors come into the classroom and present their unique stories along with facts about the disease, reached nearly 11,000 medical, nursing and physician assistant students. Program participants consistently report that the presentation is effective in increasing their knowledge about the signs and symptoms of ovarian cancer. We are also successfully providing supportive services to women and families facing an ovarian cancer diagnosis. Over 400 women have benefitted from our Woman to Woman peer support program to date.

While great progress has been made, there's much that OCRFA—and the entire ovarian cancer community—would like to accomplish. We need to find a way to identify who is most likely to get ovarian cancer, we need to find ovarian cancer earlier or prevent it all together, and we need more effective, less toxic treatments.

Financials

Ovarian Cancer Research Alliance

Fiscal year: Jan 01 - Dec 31

Financial documents

Yes, financials were audited by an independent accountant.

Revenue vs. expenses: breakdown

SOURCE: IRS Form 990

NET GAIN/LOSS: in

Note: When component data are not available, the graph displays the total Revenue and/or Expense values.

Liquidity in 2021

SOURCE: IRS Form 990

2.76

Average of 2.83 over 10 years

Months of cash in 2021

SOURCE: IRS Form 990

8.2

Average of 8.1 over 10 years

Fringe rate in 2021

SOURCE: IRS Form 990

26%

Average of 23% over 10 years

Funding sources

Source: IRS Form 990

Assets & liabilities

Source: IRS Form 990

Financial data

SOURCE: IRS Form 990

Digitizing IRS form 990 data

Ovarian Cancer Research Alliance

Revenue & expenses

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

Fiscal year ending: Download Data

Revenue
Contributions	$14,692,279
Government Grants	$0
Program Services	$0
Investments	($173,755)
Special Events	$0
Sales	$0
Other	$73,001
Total Revenue	$14,591,525

Expenses
Program Services	$5,377,724
Administration	$514,155
Fundraising	$671,813
Total Expenses	$6,563,692
Net Gain/Loss	$8,027,833

Functional expenses
Accounting Fees	$47,000
Advertising & Promotion	$54,836
Information Technology Expenses	$0
Insurance Expenses	$2,591
Interest Expenses	$0
Investment Management Fees	$65,770
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$5,977,179
Government Grants	$25,000
Program Services	$0
Investments	($291,584)
Special Events	$0
Sales	$0
Other	$20,277
Total Revenue	$5,730,872

Expenses
Program Services	$6,346,590
Administration	$493,073
Fundraising	$417,678
Total Expenses	$7,257,341
Net Gain/Loss	($1,526,469)

Functional expenses
Accounting Fees	$44,387
Advertising & Promotion	$11,037
Information Technology Expenses	$0
Insurance Expenses	$11,410
Interest Expenses	$0
Investment Management Fees	$50,093
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$6,579,363
Government Grants	$0
Program Services	$0
Investments	$1,093,572
Special Events	$0
Sales	$0
Other	$13,896
Total Revenue	$7,686,831

Expenses
Program Services	$8,027,262
Administration	$412,514
Fundraising	$476,470
Total Expenses	$8,916,246
Net Gain/Loss	($1,229,415)

Functional expenses
Accounting Fees	$40,000
Advertising & Promotion	$19,883
Information Technology Expenses	$0
Insurance Expenses	$11,106
Interest Expenses	$0
Investment Management Fees	$64,644
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$8,773,850
Government Grants	$0
Program Services	$0
Investments	$1,165,995
Special Events	$0
Sales	$0
Other	$10,208
Total Revenue	$9,950,053

Expenses
Program Services	$6,313,878
Administration	$520,119
Fundraising	$602,850
Total Expenses	$7,436,847
Net Gain/Loss	$2,513,206

Functional expenses
Accounting Fees	$41,500
Advertising & Promotion	$14,361
Information Technology Expenses	$0
Insurance Expenses	$10,420
Interest Expenses	$0
Investment Management Fees	$132,357
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$6,437,397
Government Grants	$0
Program Services	$0
Investments	$1,785,211
Special Events	$0
Sales	$0
Other	$14,589
Total Revenue	$8,237,197

Expenses
Program Services	$6,404,929
Administration	$566,830
Fundraising	$613,336
Total Expenses	$7,585,095
Net Gain/Loss	$652,102

Functional expenses
Accounting Fees	$35,962
Advertising & Promotion	$8,555
Information Technology Expenses	$0
Insurance Expenses	$9,495
Interest Expenses	$0
Investment Management Fees	$105,276
Legal Fees	$509
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$7,642,696
Government Grants	$0
Program Services	$0
Investments	$1,682,334
Special Events	$0
Sales	$0
Other	$5,900
Total Revenue	$9,330,930

Expenses
Program Services	$7,447,633
Administration	$548,591
Fundraising	$637,326
Total Expenses	$8,633,550
Net Gain/Loss	$697,380

Functional expenses
Accounting Fees	$40,000
Advertising & Promotion	$9,791
Information Technology Expenses	$0
Insurance Expenses	$10,116
Interest Expenses	$0
Investment Management Fees	$95,285
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$7,422,312
Government Grants	$0
Program Services	$0
Investments	$1,204,691
Special Events	$0
Sales	$0
Other	$209,440
Total Revenue	$8,836,443

Expenses
Program Services	$7,064,888
Administration	$575,666
Fundraising	$727,601
Total Expenses	$8,368,155
Net Gain/Loss	$468,288

Functional expenses
Accounting Fees	$35,000
Advertising & Promotion	$8,092
Information Technology Expenses	$0
Insurance Expenses	$13,060
Interest Expenses	$0
Investment Management Fees	$93,133
Legal Fees	$0
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$6,531,736
Government Grants	$0
Program Services	$0
Investments	$603,294
Special Events	$0
Sales	$0
Other	$3,259
Total Revenue	$7,138,289

Expenses
Program Services	$6,861,939
Administration	$728,332
Fundraising	$754,946
Total Expenses	$8,345,217
Net Gain/Loss	($1,206,928)

Functional expenses
Accounting Fees	$35,000
Advertising & Promotion	$203
Information Technology Expenses	$0
Insurance Expenses	$23,443
Interest Expenses	$0
Investment Management Fees	$98,824
Legal Fees	$130,430
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$10,273,853
Government Grants	$0
Program Services	$336,392
Investments	$645,686
Special Events	$0
Sales	$0
Other	$33
Total Revenue	$11,255,964

Expenses
Program Services	$8,767,394
Administration	$949,160
Fundraising	$949,963
Total Expenses	$10,666,517
Net Gain/Loss	$589,447

Functional expenses
Accounting Fees	$56,638
Advertising & Promotion	$11,774
Information Technology Expenses	$0
Insurance Expenses	$28,354
Interest Expenses	$0
Investment Management Fees	$99,141
Legal Fees	$50,805
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$9,125,500
Government Grants	$0
Program Services	$279,380
Investments	$1,877,109
Special Events	$0
Sales	$0
Other	$287
Total Revenue	$11,282,276

Expenses
Program Services	$8,664,667
Administration	$1,018,661
Fundraising	$1,121,849
Total Expenses	$10,805,177
Net Gain/Loss	$477,099

Functional expenses
Accounting Fees	$38,500
Advertising & Promotion	$35,161
Information Technology Expenses	$0
Insurance Expenses	$16,127
Interest Expenses	$0
Investment Management Fees	$108,176
Legal Fees	$74,510
Pension Plan Contributions	$0
Professional Fundraising Expenses	$0

Revenue
Contributions	$7,710,015
Government Grants	$0
Program Services	$429,150
Investments	$1,582,394
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$9,721,559

Expenses
Program Services	$8,773,738
Administration	$1,054,122
Fundraising	$1,226,308
Total Expenses	$11,054,168
Net Gain/Loss	($1,332,609)

Functional expenses
Accounting Fees	$38,500
Advertising & Promotion	$4,824
Information Technology Expenses	$249,829
Insurance Expenses	$31,528
Interest Expenses	$0
Investment Management Fees	$85,871
Legal Fees	$150,856
Pension Plan Contributions	$47,110
Professional Fundraising Expenses	$0

Revenue
Contributions	$7,042,129
Government Grants	$0
Program Services	$376,127
Investments	$991,512
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$8,409,768

Expenses
Program Services	$8,568,732
Administration	$999,164
Fundraising	$1,117,069
Total Expenses	$10,684,965
Net Gain/Loss	($2,275,197)

Functional expenses
Accounting Fees	$37,833
Advertising & Promotion	$23,986
Information Technology Expenses	$285,108
Insurance Expenses	$40,117
Interest Expenses	$0
Investment Management Fees	$58,222
Legal Fees	$11,430
Pension Plan Contributions	$44,615
Professional Fundraising Expenses	$0

Revenue
Contributions	$5,822,238
Government Grants	$402,581
Program Services	$442,712
Investments	$1,059,235
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$7,726,766

Expenses
Program Services	$6,356,692
Administration	$969,566
Fundraising	$1,033,747
Total Expenses	$8,360,005
Net Gain/Loss	($633,239)

Functional expenses
Accounting Fees	$40,000
Advertising & Promotion	$7,143
Information Technology Expenses	$232,004
Insurance Expenses	$16,433
Interest Expenses	$0
Investment Management Fees	$72,124
Legal Fees	$8,506
Pension Plan Contributions	$48,755
Professional Fundraising Expenses	$0

Revenue
Contributions	$10,860,034
Government Grants	$403,500
Program Services	$311,153
Investments	$1,513,514
Special Events	$0
Sales	$0
Other	$0
Total Revenue	$13,088,201

Expenses
Program Services	$8,890,590
Administration	$1,098,725
Fundraising	$1,103,616
Total Expenses	$11,092,931
Net Gain/Loss	$1,995,270

Functional expenses
Accounting Fees	$40,000
Advertising & Promotion	$4,461
Information Technology Expenses	$247,412
Insurance Expenses	$27,093
Interest Expenses	$0
Investment Management Fees	$89,397
Legal Fees	$34,630
Pension Plan Contributions	$49,499
Professional Fundraising Expenses	$0

Ovarian Cancer Research Alliance

Balance sheet

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot survive long, but the types of assets and liabilities must also be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan, and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Fiscal year ending: Download Data

Assets	Jan 01, 2008	Dec 31, 2008	Change
Contributions	$14,692,279
Cash & Equivalents	$3,013,149	$4,500,084	$1,486,935
Accounts Receivable	$503,197	$468,815	($34,382)
Pledges & Grants Receivable	$0	$4,000,000	$4,000,000
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$12,877,379	$13,318,767	$441,388
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$24,460	$39,841	$15,381
Other	$45,801	$36,083	($9,718)
Total Assets	$16,463,986	$22,363,590	$5,899,604

Liabilities	Jan 01, 2008	Dec 31, 2008	Change
Accounts Payable	$50,331	$37,334	($12,997)
Grants Payable	$4,200,000	$4,400,000	$200,000
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$645	$0	($645)
Total Liabilities	$4,250,976	$4,437,334	$186,358

Fund balance	Jan 01, 2008	Dec 31, 2008	Change
Temporarily Restricted Net Assets	$10,565,721	$15,695,118	$5,129,397
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$10,565,721	$15,695,118	$5,129,397
Unrestricted Net Assets	$1,647,289	$2,231,138	$583,849
Net Assets	$12,213,010	$17,926,256	$5,713,246

Assets	Jan 01, 2009	Dec 31, 2009	Change
Contributions	$5,977,179
Cash & Equivalents	$4,500,084	$5,176,458	$676,374
Accounts Receivable	$468,815	$466,940	($1,875)
Pledges & Grants Receivable	$4,000,000	$2,000,000	($2,000,000)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$13,318,767	$15,078,753	$1,759,986
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$39,841	$28,399	($11,442)
Other	$36,083	$36,053	($30)
Total Assets	$22,363,590	$22,786,603	$423,013

Liabilities	Jan 01, 2009	Dec 31, 2009	Change
Accounts Payable	$37,334	$123,257	$85,923
Grants Payable	$4,400,000	$4,387,492	($12,508)
Deferred Revenue	$0	$0	$0
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$4,437,334	$4,510,749	$73,415

Fund balance	Jan 01, 2009	Dec 31, 2009	Change
Temporarily Restricted Net Assets	$15,695,118	$12,102,607	-$3,592,511
Permanently Restricted Net Assets	$0	$0	$0
Total Restricted Net Assets	$15,695,118	$12,102,607	($3,592,511)
Unrestricted Net Assets	$2,231,138	$6,173,247	$3,942,109
Net Assets	$17,926,256	$18,275,854	$349,598

Assets	Jan 01, 2010	Dec 31, 2010	Change
Contributions	$6,579,363
Cash & Equivalents	$5,176,458	$5,331,535	$155,077
Accounts Receivable	$466,940	$356,233	($110,707)
Pledges & Grants Receivable	$2,000,000	$0	($2,000,000)
Receivable, Other	$0	$0	$0
Inventories for Sale or Use	$0	$0	$0
Investment, Securities	$15,078,753	$19,199,622	$4,120,869
Investment, Other	$0	$0	$0
Fixed Assets (LBE - Depreciation)	$28,399	$17,803	($10,596)
Other	$36,053	$105,309	$69,256
Total Assets	$22,786,603	$25,010,502	$2,223,899

Liabilities	Jan 01, 2010	Dec 31, 2010	Change
Accounts Payable	$123,257	$17,922	($105,335)
Grants Payable	$4,387,492	$7,594,083	$3,206,591
Deferred Revenue	$0	$323,000	$323,000
Loans and Notes	$0	$0	$0
Tax-Exempt Bond Liabilities	$0	$0	$0
Other	$0	$0	$0
Total Liabilities	$4,510,749	$7,935,005	$3,424,256

Ovarian Cancer Research Alliance

Financial trends analysis Glossary & formula definitions

Fiscal Year: Jan 01 - Dec 31

SOURCE: IRS Form 990 info

This snapshot of Ovarian Cancer Research Alliance’s financial trends applies Nonprofit Finance Fund® analysis to data hosted by GuideStar. While it highlights the data that matter most, remember that context is key – numbers only tell part of any story.

Created in partnership with

Fiscal year: Jan 01 - Dec 31 View full report Download data

Business model indicators

Profitability	2017	2018	2019	2020	2021
Unrestricted surplus (deficit) before depreciation	$1,893,527	-$4,239,481	$443,378	$304,736	$242,410
As % of expenses	17.5%	-38.4%	4.1%	3.6%	2.2%
Unrestricted surplus (deficit) after depreciation	$1,893,527	-$4,245,342	$443,378	$304,736	$242,410
As % of expenses	17.5%	-38.4%	4.1%	3.6%	2.2%

Revenue composition
Total revenue (unrestricted & restricted)	$11,282,276	$9,721,559	$8,409,768	$7,726,766	$13,088,201
Total revenue, % change over prior year	0.2%	-13.8%	-13.5%	-8.1%	69.4%
Program services revenue	2.5%	4.4%	4.5%	5.7%	2.4%
Membership dues	0.0%	0.0%	0.0%	0.0%	0.0%
Investment income	5.7%	7.0%	8.0%	7.9%	4.1%
Government grants	0.0%	0.0%	0.0%	5.2%	3.1%
All other grants and contributions	80.9%	79.3%	83.7%	75.4%	83.0%
Other revenue	11.0%	9.3%	3.8%	5.8%	7.4%

Expense composition
Total expenses before depreciation	$10,805,177	$11,048,307	$10,684,965	$8,360,005	$11,092,931
Total expenses, % change over prior year	1.3%	2.3%	-3.3%	-21.8%	32.7%
Personnel	20.6%	21.3%	22.0%	29.2%	22.7%
Professional fees	3.0%	3.6%	3.2%	4.9%	4.8%
Occupancy	4.4%	4.9%	3.7%	5.2%	3.9%
Interest	0.0%	0.0%	0.0%	0.0%	0.0%
Pass-through	63.0%	60.4%	60.8%	50.8%	60.8%
All other expenses	9.0%	9.8%	10.3%	9.8%	7.8%

Full cost components (estimated)	2017	2018	2019	2020	2021
Total expenses (after depreciation)	$10,805,177	$11,054,168	$10,684,965	$8,360,005	$11,092,931
One month of savings	$900,431	$920,692	$890,414	$696,667	$924,411
Debt principal payment	$0	$0	$0	$0	$0
Fixed asset additions	$15,452	$0	$0	$0	$13,431
Total full costs (estimated)	$11,721,060	$11,974,860	$11,575,379	$9,056,672	$12,030,773

Capital structure indicators

Liquidity	2017	2018	2019	2020	2021
Months of cash	7.3	2.7	6.6	8.0	8.2
Months of cash and investments	34.7	29.0	33.1	41.1	34.4
Months of estimated liquid unrestricted net assets	24.8	19.6	20.8	27.0	20.6

Balance sheet composition	2017	2018	2019	2020	2021
Cash	$6,588,663	$2,462,822	$5,868,022	$5,583,811	$7,621,446
Investments	$24,668,857	$24,232,637	$23,641,752	$23,044,897	$24,148,601
Receivables	$1,440,975	$2,013,892	$882,847	$641,801	$848,522
Gross land, buildings, equipment (LBE)	$187,068	$187,068	$187,068	$187,068	$216,165
Accumulated depreciation (as a % of LBE)	82.9%	86.0%	93.6%	96.8%	91.0%
Liabilities (as a % of assets)	31.5%	36.0%	37.6%	33.2%	35.8%
Unrestricted net assets	$22,322,148	$18,076,806	$18,520,184	$18,824,920	$19,067,330
Temporarily restricted net assets	$188,799	$367,338	N/A	N/A	N/A
Permanently restricted net assets	$0	$0	N/A	N/A	N/A
Total restricted net assets	$188,799	$367,338	$479,708	$806,570	$2,096,126
Total net assets	$22,510,947	$18,444,144	$18,999,892	$19,631,490	$21,163,456

Key data checks

Key data checks	2017	2018	2019	2020	2021
Material data errors	No	No	No	No	No

Operations

The people, governance practices, and partners that make the organization tick.

Documents

Letter of Determination is not available for this organization

Form 1023/1024 is not available for this organization

President & CEO

Ms. Audra Moran

Audra L. Moran is the President and CEO of OCRFA, a position she has held since March, 2010. Audra is committed to promoting medical research and support programs for women and their families going through a diagnosis, as well as to finding a cure for ovarian cancer.

Number of employees

Source: IRS Form 990

Ovarian Cancer Research Alliance

Officers, directors, trustees, and key employees

SOURCE: IRS Form 990

Compensation

Other

Show data for fiscal year

Compensation data

Download up to 5 most recent years of officer and director compensation data for this organization

Ovarian Cancer Research Alliance

Highest paid employees

SOURCE: IRS Form 990

Compensation

Other

Show data for fiscal year

Compensation data

Download up to 5 most recent years of highest paid employee data for this organization

Ovarian Cancer Research Alliance

Board of directors
as of 06/07/2023

SOURCE: Self-reported by organization

Board of directors data

Download the most recent year of board of directors data for this organization

Board chair

Mr. John Orrico

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

Board orientation and education
Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
CEO oversight
Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
Ethics and transparency
Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
Board composition
Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
Board performance
Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes

Organizational demographics

SOURCE: Self-reported; last updated 10/8/2021

Candid has made improvements to the race and ethnicity options.

Who works and leads organizations that serve our diverse communities? Candid partnered with CHANGE Philanthropy on this demographic section.

Leadership

The organization's leader identifies as:

Race & ethnicity

Decline to state

Sexual orientation

Decline to state

Disability status

Decline to state

Race & ethnicity

No data

Gender identity

No data

Sexual orientation

No data

Disability

No data

Contractors

Fiscal year ending

There are no fundraisers recorded for this organization.

Related organizations & associated domestic grants

Show data for fiscal year

Ovarian Cancer Research Alliance

Research. Advocacy. Support.

Mission

Is this your nonprofit?

Programs and results

Reports and documents

What we aim to solve

This profile needs more info.

Our programs

Woman to Woman

Ovarian Cancer National Conference

Survivors Teaching Students (STS)

Research Grants

Advocate Leaders

Research Advocacy

Where we work

Goals & Strategy

Charting impact

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

What have they accomplished so far and what's next?

Financials

Financial documents

Revenue vs. expenses: breakdown

Liquidity in 2021 info

2.76

Months of cash in 2021 info

8.2

Fringe rate in 2021 info

26%

Funding sources info

Assets & liabilities info

Financial data

Digitizing IRS form 990 data

Ovarian Cancer Research Alliance

Ovarian Cancer Research Alliance

Ovarian Cancer Research Alliance

Business model indicators

Capital structure indicators

Key data checks

Operations

Documents

President & CEO

Ms. Audra Moran

Number of employees

Ovarian Cancer Research Alliance

Compensation data

Ovarian Cancer Research Alliance

Compensation data

Ovarian Cancer Research Alliance

Board of directors data

Mr. John Orrico

Board leadership practices

Board orientation and education

CEO oversight

Ethics and transparency

Board composition

Board performance

Organizational demographics

Leadership

Race & ethnicity

Gender identity

Sexual orientation

Disability

Contractors

Related organizations & associated domestic grants

Liquidity in 2021

Months of cash in 2021

Fringe rate in 2021

Funding sources

Assets & liabilities